BriaCell Therapeutics (BCT) Competitors

BriaCell Therapeutics (TSE:BCT) and Sernova (TSE:SVA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk, profitability and community ranking.

Does the media refer more to BCT or SVA?

In the previous week, BriaCell Therapeutics and BriaCell Therapeutics both had 1 articles in the media. Sernova's average media sentiment score of 0.00 beat BriaCell Therapeutics' score of -1.05 indicating that Sernova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BriaCell Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Sernova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor BCT or SVA?

Sernova received 10 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 91.67% of users gave Sernova an outperform vote.

Company	Underperform	Outperform
BriaCell Therapeutics	Outperform Votes 1 100.00%	Underperform Votes No Votes
Sernova	Outperform Votes 11 91.67%	Underperform Votes 1 8.33%

Do institutionals and insiders believe in BCT or SVA?

15.0% of BriaCell Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Sernova shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by company insiders. Comparatively, 12.1% of Sernova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has better earnings and valuation, BCT or SVA?

BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BriaCell Therapeutics	N/A	N/A	-C$2.37M	-C$1.32	-6.38
Sernova	N/A	N/A	-C$35.70M	-C$0.10	-1.98

Which has more volatility and risk, BCT or SVA?

BriaCell Therapeutics has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, Sernova has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.

Do analysts recommend BCT or SVA?

Sernova has a consensus price target of C$2.00, indicating a potential upside of 875.61%. Given Sernova's stronger consensus rating and higher probable upside, analysts clearly believe Sernova is more favorable than BriaCell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BriaCell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sernova	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Is BCT or SVA more profitable?

BriaCell Therapeutics' return on equity of 536.29% beat Sernova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BriaCell Therapeutics	N/A	536.29%	-122.71%
Sernova	N/A	473.85%	-119.26%

Summary

Sernova beats BriaCell Therapeutics on 10 of the 15 factors compared between the two stocks.